LNP

Corner Therapeutics Announces First Publication on Proprietary Catalytic Adjuvant Platform

Retrieved on: 
Wednesday, November 8, 2023
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Oncology, Vaccine, DC, Antigen, MBio, Lipid, Cytokine, Infection, Virus, Protein, Observation, Pain scale, Corner, B cell, Lung, Vaccination, Immune system, COVID-19, Immunity, Medicine, Cancer, Messenger, Blood, Nobel Prize, Therapy, Nobel Prize in Physiology or Medicine, Patient, Doctor of Philosophy, Physiology, LNP

Corner Therapeutics , a biotechnology company exploiting a new scientific paradigm to boost the immune response to disease, today announced the first publication detailing their proprietary Catalytic Adjuvant platform that drives strong T cell immune responses to mRNA vaccines.

Key Points: 
  • Corner Therapeutics , a biotechnology company exploiting a new scientific paradigm to boost the immune response to disease, today announced the first publication detailing their proprietary Catalytic Adjuvant platform that drives strong T cell immune responses to mRNA vaccines.
  • The enhanced T cell immunogenicity of Corner Therapeutics’ Catalytic Adjuvant platform was also observed for antibody production.
  • “This publication is an exciting milestone for Corner Therapeutics, offering the first overview of our catalytic adjuvants as tools to stimulate unprecedented vaccine immunogenicity,” said Jonathan Kagan, Ph.D., Scientific Co-founder and Advisor at Corner Therapeutics and lead author of the publication.
  • “As we continue to develop our Catalytic Adjuvant platform, we look forward to exploring its broad potential to generate lifelong immunity for patients young and old.”

CRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Sessions 2023

Retrieved on: 
Monday, November 6, 2023
Gene editing, Dyslipidemia, Guide, Single, Plasma, Primate, Cas9, RNA, Human, Moyamoya disease, CRISPR, American Heart Association, Liver, CRISPR Therapeutics, Risk, Triglyceride, CRSP, LNP, Lipoprotein(a), FACP, AHA, Therapy, Patient, Atherosclerosis, Cardiovascular disease, Pharmaceutical industry, ANGPTL3

ZUG, Switzerland and BOSTON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced preclinical data from the Company’s investigational programs for the treatment of cardiovascular disease, at the American Heart Association (AHA) Scientific Sessions 2023.

Key Points: 
  • ZUG, Switzerland and BOSTON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced preclinical data from the Company’s investigational programs for the treatment of cardiovascular disease, at the American Heart Association (AHA) Scientific Sessions 2023.
  • “We’re excited to share these preclinical data at AHA highlighting the progress made across our in vivo programs targeting ANGPTL3 and Lp(a).
  • The findings demonstrate the potential of a one-time treatment to produce clinically meaningful, long-lasting reductions in risk factors for atherosclerotic cardiovascular disease,” said Phuong Khanh (P.K.)
  • These data suggest CTX320 has the potential to be used to reduce plasma Lp(a) levels in humans.

Genevant Sciences to Collaborate with Novo Nordisk to Develop Gene Editing Treatment for Hemophilia A

Retrieved on: 
Monday, November 6, 2023
Gene editing, Carla Geneve, Haemophilia, Therapy, RNA, Megat Burhainuddin, Novo Nordisk, Exercise, Gene, LNP, Vaccine

VANCOUVER, British Columbia, and BASEL, Switzerland, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and an expansive lipid nanoparticle (LNP) patent portfolio, today announced that it has entered into a collaboration and nonexclusive license agreement with Novo Nordisk to combine Genevant’s proprietary LNP technology with innovative mRNA-based megaTAL technology to develop an in vivo gene editing treatment for hemophilia A. Genevant’s collaboration with Novo Nordisk builds upon a joint research and development collaboration in hemophilia A between Novo Nordisk and 2seventy bio previously announced by 2seventy bio.

Key Points: 
  • VANCOUVER, British Columbia, and BASEL, Switzerland, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and an expansive lipid nanoparticle (LNP) patent portfolio, today announced that it has entered into a collaboration and nonexclusive license agreement with Novo Nordisk to combine Genevant’s proprietary LNP technology with innovative mRNA-based megaTAL technology to develop an in vivo gene editing treatment for hemophilia A. Genevant’s collaboration with Novo Nordisk builds upon a joint research and development collaboration in hemophilia A between Novo Nordisk and 2seventy bio previously announced by 2seventy bio.
  • “We are thrilled to work with Novo Nordisk in the development of a potentially transformative gene editing treatment for a patient population in need of novel therapeutic approaches,” said Pete Lutwyche, Ph.D., President and Chief Executive Officer of Genevant Sciences.
  • The agreement announced today arises from the exercise of an option under a prior agreement between Genevant and 2seventy bio and subsequently assigned by 2seventy bio to Novo Nordisk.
  • The financial terms of the agreement are in accordance with the option agreement negotiated between Genevant and 2seventy bio and as announced by 2seventy bio in January 2022.

Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Friday, November 3, 2023
Gene editing, International Symposium on Endovascular Therapy, FDA, Research, Food, Rhodopsin, Human, Congress, Fragile X syndrome, G&A, Liver, CFTR, Chromosomal translocation, Regulation of tobacco by the U.S. Food and Drug Administration, Cell, Initial, R, Society, ASH, RHO, Tissue, Lung, Cystic fibrosis, Prime editing, Gene, Composition, Abstract, LNP, Eye, Safety, European Society of Clinical Microbiology and Infectious Diseases, Investment, CGD, Patient, Retina, NHP, Patent, D, Vaccine, Pharmaceutical industry, Fine chemical, Beef cattle, Video game, Cryptocurrency, IND

CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided business updates for the third quarter ended September 30, 2023.

Key Points: 
  • 11,795,452 --
    CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided business updates for the third quarter ended September 30, 2023.
  • Together, these encouraging results mark meaningful progress toward the clinic and support our strategy of simultaneously advancing multiple programs forward.
  • In August 2023, Prime Medicine received Rare Pediatric Drug designation (RPDD) from the U.S. Food and Drug Administration (FDA) for PM359.
  • Year-to-date, Prime Medicine continues to make significant progress, executing against key initiatives to drive its Prime Editing platform forward.

TriLink BioTechnologies® Expands Capabilities with Launch of ‘Analytical Sciences Center of Excellence’

Retrieved on: 
Thursday, November 2, 2023
FDA, Health, Infectious Diseases, Research, Science, Biotechnology, Laboratory, Dicarboxylic acid, NMR, Therapy, Vaccine, CDMO, ASCE, DNA, Growth, NGS, Melamaravakkadu, Messenger, LNP, Education, Communities and Justice Directorates, GM, Quality control, Fine chemical

TriLink BioTechnologies ® (TriLink), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has launched its Analytical Sciences Center of Excellence (ASCE) hub.

Key Points: 
  • TriLink BioTechnologies ® (TriLink), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has launched its Analytical Sciences Center of Excellence (ASCE) hub.
  • Expanding its comprehensive suite of analytical testing capabilities, this new center of excellence will minimize the delays and unexpected costs typically associated with outsourced testing to multiple laboratories.
  • This new center of excellence will serve as the hub for all analytical innovation and the Quality Control laboratories across the organization’s manufacturing network.
  • “TriLink's new Analytical Sciences Center of Excellence will be a transformative force in the development of nucleic acid therapies,” shared Khaled Yamout, Senior Director of Analytical Services at TriLink.

Vernal Biosciences Showcases Cutting-Edge Innovations at the 11th International mRNA Health Conference in Berlin

Retrieved on: 
Monday, October 30, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Where U Been? (song), Therapy, RNA, Cap 1, Conference, CDMO, Research, Tail, Multimedia, IVT, Messenger, LNP, Patient, DNA, Vaccine

Vernal Biosciences, a leading Contract Development and Manufacturing Organization (CDMO) specializing in mRNA and LNP manufacturing, proudly announces its participation in the 11th International mRNA Health Conference held in Berlin.

Key Points: 
  • Vernal Biosciences, a leading Contract Development and Manufacturing Organization (CDMO) specializing in mRNA and LNP manufacturing, proudly announces its participation in the 11th International mRNA Health Conference held in Berlin.
  • At the conference, Vernal Biosciences will unveil three groundbreaking posters that highlight innovative advancements in mRNA technologies and the flexibility of Vernal’s platform process technologies.
  • Dr. Christian Cobaugh, Chief Executive Officer at Vernal Biosciences, stated, "We are excited to share these groundbreaking findings at the 11th International mRNA Health Conference.
  • The 11th International mRNA Health Conference is a premier platform for industry leaders and researchers to exchange ideas and drive innovations in mRNA therapeutics.

ReNAgade Therapeutics to Present Preclinical Data Demonstrating Potent Extra-Hepatic Delivery of mRNA Using Proprietary Lipid Nanoparticles at 11th International mRNA Health Conference

Retrieved on: 
Monday, October 30, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Stem cell, RNA, Renegade, LNP, Liver, Conference, Cell, CD34, NK, Messenger, MPP, Therapy, NHP, HSPC, Vaccine

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced it will present preclinical data demonstrating novel and proprietary lipid nanoparticle (LNP)-based delivery of mRNA to extra-hepatic tissue in a plenary session at the 11th International mRNA Health Conference, being held October 31 to November 2, 2023 in Berlin, Germany.

Key Points: 
  • ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced it will present preclinical data demonstrating novel and proprietary lipid nanoparticle (LNP)-based delivery of mRNA to extra-hepatic tissue in a plenary session at the 11th International mRNA Health Conference, being held October 31 to November 2, 2023 in Berlin, Germany.
  • “Delivery to extra-hepatic tissue is foundational to our approach, and these data help validate how our diverse LNP library can complement our multi-modal RNA platform to create a robust therapeutic pipeline.
  • Proprietary LNP delivery to natural killer (NK) cells was also identified via a high-throughput, functional barcoding screening in NHP models.
  • Taken together, potent delivery of ReNAgade’s proprietary LNPs was observed in natural killer cells and several subsets of HSCs over multiple animal models (including NHP and humanized murine models), demonstrating robust LNP delivery of mRNA cargo to extra-hepatic tissue.

Xtalks Announces its Life Science Webinar Calendar for November 2023

Retrieved on: 
Wednesday, November 1, 2023
Patient, Consciousness, The Lightning Process, ICON, Biomarker, Food, RNA, Pharmacovigilance, Drug discovery, Transformation, Vaccine, Regulation, Safety, Synergy, Unseen, Artificial intelligence, Practice, Utility, PK, Messenger, LNP, Human voice, Health, Tumor microenvironment, Bone marrow, Plasmid, Collection, Pharmaceutical industry, Medical device, Xtalk

TORONTO, Nov. 1, 2023 /PRNewswire-PRWeb/ -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries. Access to all webinars is free, so be sure to register today to save your place! Participate in the discussion and stay relevant in your field!

Key Points: 
  • Upcoming free, educational webinars from Xtalks will feature topics on biomarkers, clinical trials, commercialization & HEOR, drug discovery & development, food, fundamental research, healthcare, laboratory technology, medical device, patient recruitment & retention, pharmaceutical, pharma manufacturing & supply chain, pharmacovigilance and preclinical.
  • TORONTO, Nov. 1, 2023 /PRNewswire-PRWeb/ -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries.
  • Access to all webinars is free, so be sure to register today to save your place!
  • Participate in the discussion and stay relevant in your field!

Carisma Presents Pre-Clinical Proof of Concept for in vivo CAR-M using mRNA platform in collaboration with Moderna at SITC

Retrieved on: 
Tuesday, October 31, 2023
CAR, Therapy, Society for Immunotherapy of Cancer, CARM, Doctor of Philosophy, Entrepreneurship, SITC, Immunotherapy, Doctor of Pharmacy, Messenger, Annual general meeting, LNP, PT, Society, Cancer, Patient, Myelocyte, Pharmaceutical industry, Vaccine, Mitsubishi Carisma, Moderna

PHILADELPHIA, Oct. 31, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that it will present new findings at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting regarding its first-of-its-kind collaboration with Moderna. The collaboration aims to bring together Carisma's chimeric antigen receptor macrophage (CAR-M) platform with Moderna's mRNA and lipid nanoparticle (LNP) technologies to generate and develop in vivo CAR-M therapeutics.

Key Points: 
  • The collaboration aims to bring together Carisma's chimeric antigen receptor macrophage (CAR-M) platform with Moderna's mRNA and lipid nanoparticle (LNP) technologies to generate and develop in vivo CAR-M therapeutics.
  • Accepted as a late-breaking presentation, " In vivo CAR-M: Redirecting endogenous myeloid cells with mRNA for cancer immunotherapy ," showcases data that demonstrate Carisma's CAR-M therapy can be directly produced in vivo, or within the body, successfully redirecting endogenous myeloid cells against tumor-associated antigens using mRNA/LNP.
  • "We are pleased to share data about the successful application of our mRNA platform to advance in vivo cell therapy," said Lin Guey, PhD, Chief Scientific Officer of External Research Ventures at Moderna.
  • Details of Carisma data accepted for presentation at the SITC 38th Annual Meeting are as follows:

Kernal Biologics to Present at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Retrieved on: 
Tuesday, October 31, 2023
Therapy, Business development, MD, Novel, Doctor of Philosophy, Poster, Quality of life, SITC, Immunotherapy, Systemic, Survival rate, Messenger, Tumor microenvironment, Society, Cancer, Patient, Pharmaceutical industry, Vaccine, LNP

CAMBRIDGE, Mass., Oct. 31, 2023 /PRNewswire/ -- Kernal Biologics, Inc. (Kernal Bio) — a development-stage mRNA-technology company developing cancer therapeutics designed to improve patients' survival rate and quality of life — today announced it is presenting a poster at the Society for Immunotherapy of Cancer 2023 Annual Meeting on Friday, November 3, 2023 in San Diego, CA.

Key Points: 
  • KR-336 Data Support Use of Onco-selective mRNA LNPs as a Novel, Promising Modality for Systemic Immuno-oncology Applications
    CAMBRIDGE, Mass., Oct. 31, 2023 /PRNewswire/ -- Kernal Biologics, Inc. (Kernal Bio) — a development-stage mRNA-technology company developing cancer therapeutics designed to improve patients' survival rate and quality of life — today announced it is presenting a poster at the Society for Immunotherapy of Cancer 2023 Annual Meeting on Friday, November 3, 2023 in San Diego, CA.
  • The poster presentation features preclinical insights into KR-336, an onco-selective mRNA LNP therapeutic that Kernal Bio has rationally designed using their mRNA2.0 platform to be selectively translated into therapeutic protein within the tumor microenvironment.
  • "At SITC, we look forward to reporting the outcome of in vivo proof-of-concept studies for systemic mRNA LNP administration, which resulted in robust anti-tumor effectiveness."
  • Details for the Kernal Bio presentation are as follows:
    Poster Presentation: Systemically Administered Onco-Selective mRNA LNP Achieves Tumor Regression and Improves Overall Survival, As Monotherapy
    Presenter: Matthew Strout, MD, PhD, Vice President of Business Development, Kernal Biologics